We came across a bullish\u00a0thesis on C4 Therapeutics, Inc. on Ridire Research\u2019s Substack. In this article, we will summarize the bulls\u2019 thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th.<\/p>\n Copyright: dolgachov \/ 123RF Stock Photo<\/p>\n C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins,\u00a0stands at the forefront of targeted protein degradation (TPD), a next-generation approach in precision oncology that\u00a0eliminates\u00a0disease-causing proteins rather than inhibiting them. Unlike traditional small molecules, degraders achieve deeper, more durable therapeutic effects by fully removing their targets.<\/p>\n C4\u2019s proprietary E3 ligase platform chemistry, protected by robust intellectual property and\u00a0validated\u00a0by partnerships with Pfizer and Biogen, has transformed theoretical TPD science into a repeatable, data-driven drug engine. Its TORPEDO platform enables rational degrader design and rapid optimization through in silico\u00a0modeling, shortening development cycles and deepening its competitive moat.<\/p>\n Strategically, C4 focuses on orphan oncology indications such as synovial sarcoma and multiple myeloma, where its BRD9 and IKZF1\/3 degraders, CFT8634 and CFT7455, hold orphan drug designations. This focus allows for smaller, faster pivotal trials, regulatory support, and exclusivity-driven economics, creating a durable market advantage. Capital discipline complements scientific depth: by\u00a0maintaining\u00a0a lean cost structure and pursuing milestone-based partnerships, C4 extends its cash runway without diluting ownership.<\/p>\n While the biology of ligase engineering\u00a0remains\u00a0complex and scalability challenges persist, C4\u2019s in-house chemistry, clinical networks, and manufacturing\u00a0know-how\u00a0have built entry barriers for competitors. Upcoming catalysts include durable efficacy data in orphan cohorts, positive combination results with standard-of-care regimens, and milestone payments from partners that reinforce external validation.<\/p>\n Though class-wide safety and competition risks exist, C4\u2019s combination of technological, market, and operational moats positions it as one of the few independent TPD pure-plays capable of sustained value creation and strategic optionality.<\/p>\n Previously we covered a\u00a0bullish thesis<\/b> on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the company\u2019s leadership in gene editing and commercial success with Casgevy alongside Vertex Pharmaceuticals. The company\u2019s stock price has appreciated approximately by 30.21% since our coverage. This is because the thesis played out as Casgevy adoption strengthened. Ridire Research shares a similar but emphasizes on targeted protein degradation as the next frontier in precision oncology.<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/figure>\n